Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Menin inhibitors for NPM1-mutated and KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML): A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLourdes M. Mendez

Discussion

Loading...

Member takes

Overview

Systematic review reveals menin inhibitors improve complete response rates in adults with relapsed refractory AML, indicating significant safety concerns.

Key Points

  • Overall response rate improved to 59.7% for menin inhibitors in acute myeloid leukemia patients, emphasizing treatment efficacy in R/R groups.
  • The systematic review and meta-analysis included 9 studies with a total of 546 patients, providing a comprehensive safety profile.
  • Standardized quality assessment of studies revealed that 6 were high quality, confirming the robustness of conclusions drawn from data.
  • Menin inhibitors were found to have significant adverse events, including nausea and grade 3 or 4 AEs, spotlighting treatment safety aspects.

Cite This Study

Lourdes M. Mendez (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d88ahttps://doi.org/10.1182/blood-2025-5154
View Full Paper
Ask AI
Bookmark
Share